Kailera Therapeutics, Inc. balance sheet KLRA

As of Sep 30, 2026, Kailera Therapeutics, Inc. had total assets of $1.1 billion and total liabilities of $51.1 million. Stockholders' equity was $1.0 billion. It held $1.0 billion in cash and investments against $10.0 million of total debt, net cash of $1.0 billion. The current ratio, current assets divided by current liabilities, was 21.84.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
107
130
112
Short-term investments
795
786
407
Long-term investments
136
255
63
Cash and investments
1,038
1,172
582
Total current assets
920
929
530
Property and equipment, net
2
2
2
Total assets
1,082
1,211
625
Liabilities and equity
Accounts payable
9
19
7
Total current liabilities
42
84
55
Total liabilities
51
93
64
Stockholders' equity
1,031
1,118
-432
Debt
Lease liabilities
10
10
10
Total debt
10
10
10
Net cash
1,028
1,162
571
Ratios
Current ratio
21.84x
11.11x
9.67x
Debt to equity
0.01x
0.01x
—
Book value per share
7.95
8.63
-14,425.53
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KLRA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2096997

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.